InflaRx N.V. heads into its May 15 earnings call with three fresh analyst target raises, a $150 million equity raise, and a stock that has tripled in a month — a setup that rarely travels without tension.
The catalyst driving the move is clear. InflaRx priced a $150 million underwritten share offering on May 8. Rather than punishing the dilution, the market treated it as a funding endorsement for the company's C5a inhibitor izicopan. The stock added 34.5% on May 6, the day the offering was announced, and followed with further gains. From last month's close, IFRX is up 143% — arriving at $2.43, still a fraction of where the Street thinks fair value sits.
The analyst reaction has been almost uniformly bullish, and the recent moves are material. Raymond James upgraded the stock to Strong Buy on May 13 and lifted its target to $9 — more than three times the current price. HC Wainwright raised its target to $8 on May 11 while maintaining Buy. Even Cantor Fitzgerald, the most cautious of the three, doubled its target to $4. That brings the consensus mean target to around $6.08 — roughly 2.5 times Tuesday's close. Guggenheim sits at $14 and has maintained Buy through the recent volatility, though that target predates the offering dilution and may need recalibrating. The only bearish voice in the room remains Leerink Partners, which downgraded to Market Perform last December. For now, the Street direction is strongly one way.
The positioning picture is more nuanced. Short interest ticked up 20% over the past week to roughly 2.04 million shares — about 3.4% of the free float — even as the stock rallied 23%. That combination of rising shares short and a surging price suggests some traders are pressing new positions into the strength, betting the post-offering enthusiasm fades into earnings. Availability in the borrow market is still very loose at around 642% of short interest, meaning there are ample shares to borrow and no squeeze mechanics in play. Cost to borrow has held steady near 7.9% — elevated compared to a plain-vanilla biotech, but not the kind of rate that forces shorts to cover quickly. Days to cover is just one day, per the latest FINRA settlement data, which means there is no structural short squeeze coil here.
Options tell a more defensive story than the price action implies. The put/call ratio has risen to 0.197, more than two standard deviations above its 20-day average of 0.059 — the highest reading of the past year at 0.256. That is still a low absolute number, but the sharp relative jump from near-zero PCR just two weeks ago is notable. Options traders who were almost entirely positioned through calls have started adding put coverage. Whether that is hedging existing long exposure or outright bearish positioning, the shift in sentiment is real.
The earnings history adds further texture. IFRX reported Q1 results on May 7, and the stock moved 3.2% that day. A separate event on May 6 coincided with the 34.5% single-day jump — likely the offering news rather than a standalone earnings catalyst. Earlier in March, the stock moved roughly 6.4% the day after results. These are moderate single-day reactions for a micro-cap biotech, but the stock is heading into Thursday's print having already repriced substantially. Peers have had a mixed week: NGNE and NKTX each added around 8% and 6.5% respectively, while ABSI fell 4.5% — no clean sector signal for which way biotech sentiment runs into the week's close.
The next event to watch is Thursday's print at 4:30 PM ET, where the key question is how management frames the path for izicopan in ANCA-associated vasculitis and whether the $150 million raised buys enough runway to reach the next clinical milestone.
See the live data behind this article on ORTEX.
Open IFRX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
